Lung Cancer

Data Show Drug Triggers Anti-Angiogenesis, Apoptosis

Published in Gene Therapy Weekly, April 19th, 2001

Introgen Therapeutics, Inc. (INGN) announced March 29, 2001, that its gene therapy product candidate INGN 241, Adenoviral-mda7, may offer potential benefits in the treatment of lung cancer.

Sunil Chada, PhD, Introgen, presented the results of a preclinical study in a poster session at the 92nd Annual Meeting of the American Association for Cancer Research.

Earlier this year, Introgen announced that it was awarded a Small Business Innovation Research grant from the U.S. National Cancer Institute, which is funding this collaborative lung cancer research between Introgen and The University of Texas M.D. Anderson Cancer Center.

"The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry